This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Enzon Announces The Initiation Of Two Phase I Studies In Collaboration With The National Cancer Institute

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute (NCI), for two of the Company’s novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38). Both EZN-2968 and EZN-2208 have been shown to down-modulate HIF-1α, a subunit of HIF-1. HIF-1 is frequently overexpressed in cancer cells, where it is involved in the upregulation of gene products essential for tumor invasion, migration, angiogenesis and production of vascular endothelial growth factor (VEGF). The studies are being sponsored by the NCI under Clinical Trials Agreements with Enzon.

The first study will explore the safety and effectiveness of EZN-2968, an LNA-based antisense oligonucleotide, in patients with solid malignancies predominantly involving the liver. The second study will explore the modulation of HIF-1α in solid tumors after treatment with EZN-2208 combined with Avastin® (bevacizumab, Genentech/Roche), a humanized antibody targeting VEGF-A. Anti-angiogenic agents such as Avastin have limited efficacy, potentially as a result of the induction and up-regulation of hypoxia-inducible factors such as HIF-1α in the hypoxic conditions of the post-treatment tumor. Such effects may be offset by treatment with ENZ-2208, a topoisomerase inhibitor that down regulates HIF-1α in addition to having a cytotoxic effect.

“HIF-1α is a key element of the signaling cascade that promotes tumor growth and metastases in a wide range of cancers,” said Ivan Horak, MD, Enzon’s President of Research and Development and Chief Scientific Officer. “These two Phase I studies build on a growing body of clinical and preclinical evidence demonstrating the potential of both EZN-2968 and EZN-2208 to inhibit this important target. We look forward to collaborating with the NCI in further understanding the promise demonstrated by these two product candidates.”

The EZN-2968 study is expected to enroll 22 patients with solid tumors, predominantly involving the liver. EZN-2968 will be administered as a two-hour intravenous infusion once a week for three consecutive weeks, followed by a three-week period without drug. Tumor biopsies and other correlative imaging and pharmacodynamic studies will be performed at baseline and after drug administration.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs